Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients
Brian Ko,Kevin Tao,Lachlan Brennan,Swanand Rakhade,Cynthia X Chan,Jee-Young Moone,Richard Zhu,Ariel Sher,Samuel Wang,Yadriel Bracero,Ben Fullerton,Beth McLellan,Larisa J Geskin,Yvonne M Saenger,Cynthia X. Chan,Larisa J. Geskin,Yvonne M. Saenger
DOI: https://doi.org/10.1097/cmr.0000000000000945
2024-03-04
Melanoma Research
Abstract:Immune checkpoint inhibitors (ICI) have dramatically improved rates of overall survival (OS) for patients with metastatic melanoma [ 1–4 ]. Ipilimumab, an anti-CTLA-4 monoclonal antibody (mAb), received approval in 2011 from the USA Food and Drug Administration (FDA) for use in advanced melanoma after demonstrating significant improvement in OS when compared to chemotherapy [ 1 , 5 ]. Pembrolizumab and nivolumab, two anti-PD-1 mAb, were FDA-approved in 2014 [ 2 , 3 ]. The 2017 CheckMate 067 clinical trial demonstrated that a combination of ipilimumab and nivolumab improved survival for advanced melanoma compared with either agent alone [ 6–9 ]. Notably, 6 years of follow-up was required to demonstrate the benefit of adding anti-CTLA-4 to upfront anti-PD-1, with OS benefit demonstrated in 2022 after initial inconclusive results published in 2015, 2018, and 2019, suggesting that benefits of combination therapy are not readily apparent but emerge over time [ 6 ]. However, the combination had a significantly higher incidence of toxicity (58% versus 21% for nivolumab); despite this, it was associated with a higher quality of life [ 9–11 ]. Additionally, a systematic review and meta-analysis, the OTHERS study, found a benefit of prolonged ICI administration beyond 2 years compared to a fixed 2-year schedule in patients with melanoma [ 12 ]. Most recently, humanized, immunoglobulin G4 (IgG4) mAb directed against the inhibitory receptor lymphocyte activation gene 3 protein (anti-lag3) has gained FDA approval. There is currently no data proving that anti-lag3 improves OS, although benefit in terms of progression-free survival (PFS) has been established [ 13 , 14 ].
dermatology,oncology,medicine, research & experimental